Five-year Treatment of Chronic Venous Insufficiency with O-(β-hydroxyethyl)-rutosides: Safety Aspects

Overview

Journal Int J Angiol

Date 2012 Apr 6

PMID 22477419

Citations 2

Authors

S Stuard

Maria Rosaria Cesarone

Gianni Belcaro

Mark Dugall

Andrea Ledda

Marisa Cacchio

Andrea Ricci

Edmondo Ippolito

Andrea Di Renzo

Maria Giovanna Grossi

Affiliations

Soon will be listed here.

Abstract

Chronic venous insufficiency (CVI), and related signs and symptoms of venous and diabetic microangiopathy, can be effectively treated with O-(β-hydroxyethyl)-rutosides (HR). The aim of the present independent registry study was to evaluate HR in a long-term (five-year) period of administration that examined the tolerability and safety of HR. Patients with severe CVI and venous microangiopathy were included in the registry. Subjects who completed five years of treatment were considered in the analysis. Blood parameters, liver and renal function tests, microalbuminuria (in diabetic patients) and cholesterol levels were evaluated to assess the effects of HR treatment. Four groups were studied - group A (98 patients) received oral HR (1500 mg per day), group B (87 diabetic patients with CVI) was treated with 2 g of HR per day, group C (90 controls, including 42 diabetic patients) had no pharmacological treatment and group D (113 patients, including 48 diabetic patients) used elastic stockings. No significant negative changes in blood parameters were recorded at two and five years. Decreases in microalbuminuria and total cholesterol, and an increase in high-density lipoprotein cholesterol were observed in HR-treated patients, particularly in diabetic patients. Minimal (nonsignificant) variations were observed in the groups that did not use HR. In conclusion, HR treatment is safe, and some positive effects from HR on cholesterol levels and microalbuminuria (in diabetic patients) that were previously observed may suggest potential new clinical applications.

Citing Articles

Rutin as a Potent Antioxidant: Implications for Neurodegenerative Disorders.

Enogieru A, Haylett W, Hiss D, Bardien S, Ekpo O Oxid Med Cell Longev. 2018; 2018:6241017.

PMID: 30050657 PMC: 6040293. DOI: 10.1155/2018/6241017.

Flavonoids mixture (diosmin, troxerutin, hesperidin) in the treatment of acute hemorrhoidal disease: a prospective, randomized, triple-blind, controlled trial.

Giannini I, Amato A, Basso L, Tricomi N, Marranci M, Pecorella G Tech Coloproctol. 2015; 19(6):339-45.

PMID: 25893991 DOI: 10.1007/s10151-015-1302-9.

References

Bollinger A, Jager K, Geser A, Sgier F, Seglias J . Transcapillary and interstitial diffusion of Na-fluorescein in chronic venous insufficiency with white atrophy. Int J Microcirc Clin Exp. 1982; 1(1):5-17. View

Yang X, Wang F, Hu S . The electrochemical oxidation of troxerutin and its sensitive determination in pharmaceutical dosage forms at PVP modified carbon paste electrode. Colloids Surf B Biointerfaces. 2006; 52(1):8-13. DOI: 10.1016/j.colsurfb.2006.05.020. View

Roland I, Bougelet C, Ninane N, Arnould T, Michiels C, Remacle J . Effect of hydroxyethylrutosides on hypoxial-induced neutrophil adherence to umbilical vein endothelium. Cardiovasc Drugs Ther. 1998; 12(4):375-81. DOI: 10.1023/a:1007772817842. View

Fagrell B . Microcirculatory disturbances - the final cause for venous leg ulcers?. Vasa. 1982; 11(2):101-3. View

Poynard T, Valterio C . Meta-analysis of hydroxyethylrutosides in the treatment of chronic venous insufficiency. Vasa. 1994; 23(3):244-50. View

DeSanctis M, Cesarone M, Incandela L, Belcaro G, Acerbi G . Methods of evaluation and quantification of microangiopathy in high perfusion microangiopathy (chronic venous insufficiency and diabetic microangiopathy). J Cardiovasc Pharmacol Ther. 2002; 7 Suppl 1:S3-6. DOI: 10.1177/107424840200700102. View

Liu F, Xu Y, Rui L, Gao S, Dong H, Guo Q . Liquid chromatography/tandem mass spectrometry assay for the quantification of troxerutin in human plasma. Rapid Commun Mass Spectrom. 2006; 20(23):3522-6. DOI: 10.1002/rcm.2764. View

Furfaro A, Menini S, Patriarca S, Pesce C, Odetti P, Cottalasso D . HNE-dependent molecular damage in diabetic nephropathy and its possible prevention by N-acetyl-cysteine and oxerutin. Biofactors. 2006; 24(1-4):291-8. DOI: 10.1002/biof.5520240134. View

Cesarone M, Belcaro G, Incandela L, Geroulakos G, Griffin M, Lennox A . Flight microangiopathy in medium-to-long distance flights: prevention of edema and microcirculation alterations with HR (Paroven, Venoruton; 0-(beta-hydroxyethyl)-rutosides): a prospective, randomized, controlled trial. J Cardiovasc Pharmacol Ther. 2002; 7 Suppl 1:S17-20. DOI: 10.1177/107424840200700105. View

10.

Chung H, Choi S, Ahn B, Kwak H, Kim J, Kim W . Efficacy of troxerutin on streptozotocin-induced rat model in the early stage of diabetic retinopathy. Arzneimittelforschung. 2005; 55(10):573-80. DOI: 10.1055/s-0031-1296907. View

11.

Belcaro G, Nicolaides A, Volteas N, Leon M . Skin flow the venoarteriolar response and capillary filtration in diabetics. A 3-year follow-up. Angiology. 1992; 43(6):490-5. DOI: 10.1177/000331979204300606. View

12.

Adam B, Pentz R, Siegers C, Strubelt O, Tegtmeier M . Troxerutin protects the isolated perfused rat liver from a possible lipid peroxidation by coumarin. Phytomedicine. 2005; 12(1-2):52-61. DOI: 10.1016/j.phymed.2004.01.007. View

13.

Hsu I, Jou H, Huang C, Wang T, Wu W . The effects of soygerm extracts on blood lipoproteins, antioxidative capacity and urinary estrogen metabolites in postmenopausal women on hormone therapy. Int J Gynaecol Obstet. 2007; 98(1):29-33. DOI: 10.1016/j.ijgo.2007.03.031. View

14.

Bergan J, Schmid-Schonbein G, Takase S . Therapeutic approach to chronic venous insufficiency and its complications: place of Daflon 500 mg. Angiology. 2001; 52 Suppl 1:S43-7. DOI: 10.1177/0003319701052001S06. View

15.

Henriksen O . Local reflex in microcirculation in human subcutaneous tissue. Acta Physiol Scand. 1976; 97(4):447-56. DOI: 10.1111/j.1748-1716.1976.tb10284.x. View

16.

Franzeck U, Bollinger A, Huch R, Huch A . Transcutaneous oxygen tension and capillary morphologic characteristics and density in patients with chronic venous incompetence. Circulation. 1984; 70(5):806-11. DOI: 10.1161/01.cir.70.5.806. View

17.

Murtaugh M, Jacobs Jr D, Yu X, Gross M, Steffes M . Correlates of urinary albumin excretion in young adult blacks and whites: the Coronary Artery Risk Development in Young Adults Study. Am J Epidemiol. 2003; 158(7):676-86. DOI: 10.1093/aje/kwg208. View

18.

Belcaro G, Rulo A, CANDIANI C . Evaluation of the microcirculatory effects of Venoruton in patients with chronic venous hypertension by laserdoppler flowmetry, transcutaneous PO2 and PCO2 measurements, leg volumetry and ambulatory venous pressure measurements. Vasa. 1989; 18(2):146-51. View

19.

Belcaro G, Christopoulos D, Nicolaides A . Skin flow and swelling in post-phlebitic limbs. Vasa. 1989; 18(2):136-9. View

20.

Belcaro G, DAulerio A, Rulo A, CANDIANI C . Evaluation of capillary permeability and microcirculation in patients with chronic venous hypertension treated with venoruton by the vacuum suction chamber (VSC) device and laser-Doppler flowmetry. Phlebologie. 1988; 41(4):847-56. View